ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 366 participants.

Also called NCT07737964

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 366 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07737964
  • EU CT 2025-524344-35-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07737964. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
Acronym
ACHIEVE
Condition
Heart Failure
Intervention (Drug)
Acetazolamide
Intervention (Drug)
Furosemide
Lead sponsor
University Hospital, Montpellier (class: other)

Record details

Record id
cardio:ct-nct07737964
Content hash
a8578ea25558e02edb030b0641e31da824f504073b4fa580afd71361fe63a538